Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 5/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848677 | 0.98 | HSD17B10 (0.44) | HSD17B10TP53PARP1AKR1C3MEN1 | |
| SCHEMBL8306091 | 0.95 | HSD17B10 (0.50) | HSD17B10TP53PARP1AKR1C3MEN1 | |
| SCHEMBL8305499 | 0.84 | HSD17B10 (0.51) | HSD17B10TP53AKR1C3MEN1KMT2A | |
| SCHEMBL76589 | 0.83 | ALDH1A1 (0.45) | HSD17B10PARP1MEN1KMT2AF10 | |
| SCHEMBL29349011 | 0.81 | HSD17B10 (0.42) | HSD17B10PARP1MEN1KMT2AF10 | |
| SCHEMBL16190037 | 0.81 | PARP1 (0.42) | HSD17B10PARP1AKR1C3F10ALDH1A1 | |
| SCHEMBL85665 | 0.81 | ALDH1A1 (0.44) | HSD17B10PARP1MEN1KMT2AF10 | |
| SCHEMBL8305486 | 0.81 | HSD17B10 (0.45) | HSD17B10TP53AKR1C3MEN1KMT2A | |
| SCHEMBL17244485 | 0.81 | HSD17B10 (0.64) | HSD17B10TP53AKR1C3MEN1KMT2A | |
| SCHEMBL8136067 | 0.81 | TP53 (0.48) | TP53F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20080081814-A1 | Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa | CEZANNE BERTRAM | 2008-04-03 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20070265259-A1 | Proline Derivatives | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| US-7273867-B2 | Phenyl derivatives | MERCK PATENT GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265259-A1 | Proline Derivatives | F2, XPNPEP1, PRAP1 | HSD17B10 2651/4885TP53 452/4885PARP1 863/4885 |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | HSD17B10 3381/4885TP53 3270/4885PARP1 601/4885 |
| US-20080081814-A1 | Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa | F2, F11, F12 | HSD17B10 1254/4885TP53 1461/4885PARP1 991/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | HSD17B10 1922/4885TP53 1525/4885PARP1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.